Bristol Myers Squibb stock gains support from new multiple myeloma approval and raised earnings forecast
Published on 08/14/2026 at 16:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock (ISIN US0897961004) is holding in the mid-$60 range as of August 13, 2026, with a closing price of $64.66 on the New York Stock Exchange after investors digested a new U.S. approval for the multiple myeloma treatment ZENBEXUS and fresh earnings estimates for late 2026. Market data show the shares adding 1.50 percent on August 13, 2026, compared with the prior session, while recent research lifts projected fourth quarter 2026 earnings per share to $1.64.
Per a corporate announcement dated August 13, 2026, Bristol Myers Squibb has received accelerated approval from the U.S. Food and Drug Administration for ZENBEXUS (iberdomide) in combination with daratumumab, hyaluronidase-fihj and dexamethasone (ZDd) for adult patients with multiple myeloma who have received at least one prior line of therapy that included a proteasome inhibitor and an immunomodulatory agent. The company highlights that this ZDd regimen is supported by EXCALIBER-RRMM trial data showing minimal residual disease negative complete response rates of 41 percent with ZDd versus 21 percent for a comparator regimen of daratumumab, bortezomib and dexamethasone in relapsed or refractory multiple myeloma.
Zenbexus approval and clinical impact
The accelerated approval of ZENBEXUS marks the first FDA cleared CELMoD therapy from Bristol Myers Squibb and introduces a new class of cereblon modulating protein degraders for multiple myeloma treatment. The company release notes that ZENBEXUS is indicated for adult patients who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent, positioning the drug earlier in the treatment cascade as early as first relapse.
In the pivotal EXCALIBER-RRMM study, the ZDd combination delivered minimal residual disease negative complete response rates of 41 percent versus 21 percent for daratumumab, bortezomib and dexamethasone, effectively doubling the rate of deep responses. The EXCALIBER-RRMM data summary underscores that minimal residual disease negative complete response is a more sensitive measure of remission, which regulators used as a key endpoint for this approval.
From a safety standpoint, ZENBEXUS carries boxed warnings for embryo fetal toxicity and venous and arterial thromboembolism, and it is contraindicated in females who are pregnant. The prescribing information emphasizes that females of reproductive potential must use two effective forms of contraception or continuously abstain from heterosexual sex during treatment and for four weeks after the last dose of ZENBEXUS.
Stock performance and analyst expectations
On the market side, quote snapshots show Bristol Myers Squibb shares at $64.66 at the August 13, 2026 close, with a 1.50 percent daily gain versus the prior session as the stock trades on the New York Stock Exchange in U.S. dollars. The TradingKey overview lists the current price at $64.66, with a previous close of $64.655 and an overall market capitalization of $132.09 billion, underlining the company’s large cap status in global pharmaceuticals.
The same performance panel reports that Bristol Myers Squibb shares have risen 19.84 percent year to date based on the $64.66 price as of August 13, 2026, providing a clear contrast with the modest 0.80 percent performance earlier in the year and signaling that the stock has gained traction as recent catalysts accumulated. Sector based data further confirm the 5 day change of 1.48 percent at the $64.66 level, suggesting steady short term momentum around the latest news flow.
On the earnings front, one coverage summary published on August 14, 2026 reports that the consensus estimate for Bristol Myers Squibb’s current full year earnings stands at $6.96 per share. The same overview indicates that the fourth quarter 2026 earnings per share forecast has been increased to $1.64 from a previous estimate of $1.50, implying an upward revision of $0.14 per share for that period.
This revised fourth quarter forecast sits against a backdrop of stronger recent reported results. An industry report dated August 14, 2026 states that Bristol Myers Squibb generated $12.97 billion in total revenue in the second quarter, representing a 5 percent year on year increase and beating a consensus revenue expectation of $11.73 billion. The same analysis notes that the company lifted its 2026 sales guidance by 6 percent to $49.5 billion, underscoring the management’s confidence in the evolving portfolio that now includes ZENBEXUS.
For investors, the quantified context matters: the 5 percent revenue growth to $12.97 billion in the second quarter compares against erosion in legacy multiple myeloma brands, with one report pointing out that Revlimid sales fell 49 percent year on year to $425 million and Pomalyst dropped 71 percent to $204 million in the same quarter as generics entered the market. The coverage frames ZENBEXUS and other new therapies as part of Bristol Myers Squibb’s strategy to offset these declines.
Operational investments and long term profile
Beyond drug approvals and near term earnings, Bristol Myers Squibb is committing substantial capital to expand its manufacturing footprint in the United States. A project update dated August 13, 2026 outlines plans to invest $2.3 billion in a new biopharmaceutical manufacturing campus in Houston, Texas, with an expected size of roughly 600,000 square feet at the Generation Park site. The investment narrative indicates that this facility is expected to create 500 permanent jobs and around 2,000 construction and indirect jobs between 2027 and 2030.
The same description places the Houston project within a broader pledge to invest $40 billion in the United States over five years across research and development, technology and domestic manufacturing. A construction sector report underscores that the Houston campus is intended to support the production of advanced therapies, aligning capacity planning with the company’s late stage pipeline and recently approved assets like ZENBEXUS.
At the same time, legal and competitive dynamics continue to form part of the risk picture. One German language legal update notes that Cytokinetics, Incorporated has filed a lawsuit against Bristol Myers Squibb Company and MyoKardia, Inc. at the United States District Court for the District of Delaware related to patent disputes, highlighting ongoing litigation exposure in the cardiovascular segment. The filing summary also references Cytokinetics’ second quarter 2026 financial results, showing how competitive peers are strengthening their own positions.
Representative product Zenbexus
Zenbexus, Bristol Myers Squibb’s newly approved multiple myeloma drug, serves as a concrete example of the company’s evolving product mix. According to the August 13, 2026 approval announcement, ZENBEXUS is an oral CELMoD therapy that modulates cereblon to promote degradation of specific substrates, enhancing antitumor activity in combination with daratumumab and dexamethasone. The product description identifies ZENBEXUS as the first approved CELMoD in its class, positioned to treat adult patients with multiple myeloma after at least one prior line of therapy.
For patients and clinicians, the key practical elements include once daily oral dosing, the use of ZDd combination regimens in relapsed or refractory disease and the requirement for strict pregnancy prevention measures during treatment. The strong minimal residual disease negative complete response data and early use at first relapse could make Zenbexus an important contributor to Bristol Myers Squibb’s future multiple myeloma franchise, particularly as legacy brands like Revlimid and Pomalyst face accelerating generic erosion.
Closing stock view and current valuation
As of the August 13, 2026 close, Bristol Myers Squibb stock trades at $64.66 on the New York Stock Exchange, with the latest available quote snapshot showing a daily increase of 1.50 percent and a market capitalization of $132.09 billion in U.S. dollars. The price panel also reports a year to date performance of 19.84 percent at the $64.66 level, placing the shares above their starting value at the beginning of 2026.
For retail investors tracking large pharma names, the combination of a new multiple myeloma approval, improved second quarter revenue, a higher full year sales guidance of $49.5 billion and raised fourth quarter 2026 earnings expectations to $1.64 per share provides a detailed framework for assessing Bristol Myers Squibb’s current valuation in the mid-$60 range.
Read more
More on Bristol Myers Squibb stock and corporate developments can be found at the company’s investor relations site and in recent sector coverage highlighting the FDA approval for ZENBEXUS, second quarter 2026 financial results and long term manufacturing investments in Houston.
Fact box
Company: Bristol Myers Squibb Co.
ISIN: US0897961004
Ticker: BMY
Exchange: New York Stock Exchange
Price (as of August 13, 2026, 4:00 p.m. ET): $64.66 USD
Market cap: $132.09 billion (as of August 13, 2026)
Sector / Industry: Pharmaceuticals / Biotechnology
Index membership: S&P 500
